Batten Disease with Narcolepsy and Functional Neurological Disorder: A Case Report

Why It Matters

Identifying treatable comorbidities like narcolepsy and functional seizures prevents mismanagement of Batten disease and can substantially improve functional outcomes for affected adolescents.

Key Takeaways

• First reported FND and narcolepsy comorbidity in CLN3.
• Functional seizures misdiagnosed as disease progression.
• Armodafinil improved energy, mood, and seizure frequency.
• Early sleep testing essential for Batten disease patients.
• Treating comorbidities enhances quality of life in adolescents.

Pulse Analysis

Juvenile Batten disease, formally known as neuronal ceroid lipofuscinosis type 3, remains one of the most challenging neurodegenerative disorders for clinicians. Its hallmark features—progressive vision loss, motor decline, seizures, and cognitive deterioration—often dominate the diagnostic narrative, leaving little room for ancillary conditions. Yet the disease’s heterogeneous presentation can mask overlapping disorders, especially when patients exhibit atypical symptoms such as excessive daytime sleepiness or seizure‑like episodes that do not conform to classic epileptic patterns. Recognizing this diagnostic blind spot is crucial, as it directly influences therapeutic direction and long‑term prognosis.

Functional neurological disorder (FND) and narcolepsy share several clinical touchpoints with Batten disease, including fatigue, altered consciousness, and motor phenomena that can be mistaken for disease progression. Advanced neurophysiological tools—video‑EEG for capturing functional seizures and Multiple Sleep Latency Testing for quantifying sleep‑onset REM periods—provide objective differentiation. In the reported case, these modalities uncovered a dual comorbidity that had eluded standard psychiatric and anti‑epileptic regimens, underscoring the value of comprehensive, multidisciplinary assessment in rare disease cohorts. Early identification prevents diagnostic overshadowing, where primary disease symptoms eclipse treatable secondary conditions.

The therapeutic response to armodafinil, a wake‑promoting stimulant, illustrates the broader principle that addressing comorbidities can yield outsized benefits. By restoring daytime alertness, the medication not only alleviated narcoleptic symptoms but also stabilized mood and curtailed functional seizure frequency, outcomes that conventional Batten disease management rarely achieves. This case advocates for routine sleep evaluations and functional assessments in neurodegenerative populations, encouraging clinicians to adopt a holistic care model that integrates neurology, psychiatry, and sleep medicine. Future research should explore prevalence rates of such comorbidities in CLN3 cohorts and evaluate standardized screening protocols to optimize patient quality of life.